MA38816A - Sulfamidase modifiée et sa production - Google Patents

Sulfamidase modifiée et sa production

Info

Publication number
MA38816A
MA38816A MA038816A MA38816A MA38816A MA 38816 A MA38816 A MA 38816A MA 038816 A MA038816 A MA 038816A MA 38816 A MA38816 A MA 38816A MA 38816 A MA38816 A MA 38816A
Authority
MA
Morocco
Prior art keywords
sulfamidase
modified
modified sulfamidase
production
mammal
Prior art date
Application number
MA038816A
Other languages
English (en)
Other versions
MA38816B1 (fr
Inventor
Charlotta Berghard
Erik Nordling
Gelius Stefan Svensson
Agneta Tjernberg
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MA38816A publication Critical patent/MA38816A/fr
Publication of MA38816B1 publication Critical patent/MA38816B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une sulfamidase modifiée, une composition comprenant une sulfamidase modifiée, ainsi que des procédés de préparation d'une sulfamidase modifiée et l'utilisation thérapeutique d'une telle sulfamidase. En particulier, la présente invention concerne une sulfamidase modifiée ne comprenant pratiquement pas d'épitopes pour des récepteurs de reconnaissance de glycane, permettant ainsi le transport de ladite sulfamidase à travers la barrière hémato-encéphalique d'un mammifère, ladite sulfamidase ayant une activité catalytique dans le cerveau dudit mammifère.
MA38816A 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production MA38816B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162996 2014-04-01
EP15713502.1A EP2970413B1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production
PCT/EP2015/057256 WO2015150490A1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et son procédé de production

Publications (2)

Publication Number Publication Date
MA38816A true MA38816A (fr) 2016-01-20
MA38816B1 MA38816B1 (fr) 2018-10-31

Family

ID=50389999

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38816A MA38816B1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production

Country Status (31)

Country Link
US (2) US9982243B2 (fr)
EP (2) EP2970413B1 (fr)
JP (1) JP6594896B2 (fr)
KR (1) KR20160138282A (fr)
CN (1) CN106414727A (fr)
AU (1) AU2015239126B2 (fr)
BR (1) BR112016022333A2 (fr)
CA (1) CA2943140A1 (fr)
CL (1) CL2016002469A1 (fr)
CY (1) CY1120697T1 (fr)
DK (1) DK2970413T3 (fr)
ES (1) ES2687262T3 (fr)
HK (1) HK1231510A1 (fr)
HR (1) HRP20181507T1 (fr)
HU (1) HUE039691T2 (fr)
IL (1) IL247978A0 (fr)
LT (1) LT2970413T (fr)
MA (1) MA38816B1 (fr)
MX (1) MX368947B (fr)
PH (1) PH12016501812A1 (fr)
PL (1) PL2970413T3 (fr)
PT (1) PT2970413T (fr)
RS (1) RS57842B1 (fr)
RU (1) RU2708026C2 (fr)
SA (1) SA516371859B1 (fr)
SG (1) SG11201608025QA (fr)
SI (1) SI2970413T1 (fr)
SM (1) SMT201800511T1 (fr)
UA (1) UA120432C2 (fr)
WO (1) WO2015150490A1 (fr)
ZA (1) ZA201606492B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970413T (pt) 2014-04-01 2018-10-23 Swedish Orphan Biovitrum Ab Publ Sulfamidase modificada e sua produção
KR20180055888A (ko) * 2015-10-01 2018-05-25 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 변형된 라이소좀 단백질 및 그의 제조 방법
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
WO2019145500A1 (fr) 2018-01-26 2019-08-01 Swedish Orphan Biovitrum Ab (Publ) Méthode de traitement
US11708569B2 (en) 2018-08-29 2023-07-25 University Of Copenhagen Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
EP3741867A1 (fr) 2019-05-24 2020-11-25 Swedish Orphan Biovitrum AB (Publ) Dosage d'activité de sulfatase
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
EP1378525A3 (fr) 1996-06-07 2004-01-14 Neorx Corporation Anticorps humanisés qui se lient à l'antigène relié par l'anticorp NR-LU-13 et leur utilisation dans des méthodes de ciblage
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
AU2002347910A1 (en) 2001-10-16 2003-04-28 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
NZ537306A (en) 2002-07-01 2008-11-28 Kenneth S Warren Inst Inc Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
WO2008109677A2 (fr) * 2007-03-06 2008-09-12 Saint Louis University Enzyme modifiée et procédé de traitement
MX2010007846A (es) * 2008-01-18 2010-10-05 Biomarin Pharm Inc Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
EP2394667A1 (fr) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
WO2012085622A1 (fr) 2010-12-22 2012-06-28 Fondazione Telethon Stratégies thérapeutiques pour traiter une pathologie du snc dans des mucopolysaccharidoses
CN103764824B (zh) * 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
WO2014194427A1 (fr) 2013-06-06 2014-12-11 Angiochem Inc. Protéines de fusion iduronate-2-sulfatase ciblées
US20140377246A1 (en) 2013-06-19 2014-12-25 Carol Ann Foundation and International Morquio Organization Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme
PT2970413T (pt) 2014-04-01 2018-10-23 Swedish Orphan Biovitrum Ab Publ Sulfamidase modificada e sua produção

Also Published As

Publication number Publication date
US20160230155A1 (en) 2016-08-11
MX2016012910A (es) 2017-07-14
KR20160138282A (ko) 2016-12-02
RU2708026C2 (ru) 2019-12-03
AU2015239126B2 (en) 2019-05-02
UA120432C2 (uk) 2019-12-10
BR112016022333A2 (pt) 2017-08-15
EP2970413B1 (fr) 2018-07-04
SI2970413T1 (sl) 2018-10-30
RU2016140844A3 (fr) 2018-10-11
AU2015239126A1 (en) 2016-10-27
PH12016501812A1 (en) 2017-07-24
HUE039691T2 (hu) 2019-01-28
SG11201608025QA (en) 2016-10-28
EP3401325A1 (fr) 2018-11-14
EP2970413A1 (fr) 2016-01-20
CL2016002469A1 (es) 2017-12-15
RS57842B1 (sr) 2018-12-31
JP6594896B2 (ja) 2019-10-23
HRP20181507T1 (hr) 2018-11-16
SA516371859B1 (ar) 2019-01-17
US9982243B2 (en) 2018-05-29
PT2970413T (pt) 2018-10-23
US20180320152A1 (en) 2018-11-08
MX368947B (es) 2019-10-22
CA2943140A1 (fr) 2015-10-08
CN106414727A (zh) 2017-02-15
RU2016140844A (ru) 2018-05-10
DK2970413T3 (en) 2018-10-15
ZA201606492B (en) 2019-02-27
JP2017514462A (ja) 2017-06-08
PL2970413T3 (pl) 2018-12-31
IL247978A0 (en) 2016-11-30
LT2970413T (lt) 2018-10-10
ES2687262T3 (es) 2018-10-24
CY1120697T1 (el) 2019-12-11
MA38816B1 (fr) 2018-10-31
HK1231510A1 (zh) 2017-12-22
SMT201800511T1 (it) 2018-11-09
WO2015150490A1 (fr) 2015-10-08

Similar Documents

Publication Publication Date Title
MA38816A (fr) Sulfamidase modifiée et sa production
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
EA201491391A1 (ru) Терапевтически активные соединения и способы их применения
MX376663B (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MA39362A1 (fr) Compositions stables d'iode non complexé et procédés d'utilisation.
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MA40249A (fr) Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation
EA201590171A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
MX2018013234A (es) Sintesis de indazoles.
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
WO2015022669A3 (fr) Procédés de typage d'allèles de hla
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
WO2017066796A3 (fr) Modulateurs de maladies impliquant des télomères
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
WO2015109318A3 (fr) Méthodes thérapeutiques
MX2019002818A (es) Metodos para detectar anticuerpos neutralizantes anti-leptina.
CL2016001745A1 (es) Ácido (s)-3'-metil-abscísico y ésteres del mismo
MX2015012043A (es) Agonistas muscarinicos.